Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Acute Coronary Syndrome
  • Arterial Occlusive Diseases
  • Arteriosclerosis
  • Cardiovascular Diseases
  • Coronary (Artery) Disease
  • Coronary Disease
  • Heart Diseases
  • Myocardial Ischemia
  • Syndrome Heart Disease
  • Vascular Diseases
Type
Interventional
Phase
Phase 4
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: All patients will be randomly divided into the treatment group and control group on a 1:1 basis, based on a complete randomization. The treatment group will use aspirin + clopidogrel dual anti-platelet therapy for 12 months, and the control group will use aspirin monotherapy for 12 months.Masking: None (Open Label)Masking Description: This is an open-label trial, and the investigators and subjects will not be blinded. Under these conditions, the following methods will be employed to minimize bias: Clinical Endpoint Committee (CEC) is an independent group of experts that reviews clinical trial data in order to give expert opinions about clinical safety or efficacy events of interest; The statisticians are independent and blind to the grouping information. Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 75 years
Gender
Both males and females

Description

Not Provided

Not Provided

Tracking Information

NCT #
NCT04624854
Collaborators
  • Chinese Society of Cardiology
  • Lepu Medical Technology (Beijing) Co., Ltd.
Investigators
Principal Investigator: Bo Yu, M.D.,FACC The Second Affiliated Hospital of Harbin Medical University